Sorrento Therapeutics (NASDAQ:SRNE) will collaborate with
long-time partner Celularity to expand the therapeutic use of the
latter’s allogeneic, off-the-shelf, placental-derived natural killer
(NK) cell therapy, CYNK-001, to the prevention and treatment of
coronavirus infection, focusing on the virus responsible for the current
outbreak, 2019-nCoV.
The company says it is in contact with leading
scientists and local Chinese experts to discuss the clinical validation
and logistics required to fast track the candidate.
Sorrento owns 25% of Celularity.
Shares up 8% premarket on modestly higher volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.